⚠ Net Debt More Than Doubled in 2025Moderate threat

Johnson & Johnson (JNJ) — threat to the moat

J&J's net debt went from $12.1 billion to $27.8 billion in a single year of buying.

J&J borrowed heavily in 2025. Net debt, cash and current marketable securities net of debt, was $27.8 billion at the end of the year against $12.1 billion a year earlier1. At the end of June 2026 it was $28.2 billion, with $49.0 billion of notes payable and long-term debt against $20.8 billion of cash and marketable securities2.

Debt and cash, end of June 2026 ($bn)49.0Notes payable and long-term debt20.8Cash and marketable securities28.2Net debtJ&J Form 10-Q, Q2 2026
Debt more than twice the cash.

The debt bought Intra-Cellular, funded by approximately $9.2 billion of senior notes3. Interest expense rose to $971 million from $755 million4.

J&J can carry this comfortably. The concern is the direction: 2025's net debt was higher than at the end of 2022, when J&J had just paid $17.1 billion for Abiomed and net debt was $17.4 billion5.

The composition of the debt is conservative. Total debt was $47.9 billion at the end of 2025 against $36.6 billion a year earlier6, and the company says operating cash flows, external funding and committed credit facilities will provide sufficient resources for its needs, including the remaining talc and opioid payments7. Nothing in the numbers suggests strain; the point is that the cushion is thinner than it was.

Cash fell even as debt rose. Cash and cash equivalents were $19,709 million at the end of 2025 against $24,105 million a year earlier8, and the company averaged $22.3 billion of cash and marketable securities through the year9. The borrowing replaced cash rather than adding to it.

The measure is net debt at the end of 2026. Above $30 billion, after a year in which the company still generates about $20 billion of free cash flow, would mean the purchases and the talc payments are outrunning the cash.

References
  1. ReportedNet debt, cash and current marketable securities net of debt, was $27.8 billion at the end of the year against $12.1 billion a year earlier.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: rebate accrual tables, research and development, cost of products sold, debt and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  2. ReportedAt the end of June 2026 it was $28.2 billion, with $49.0 billion of notes payable and long-term debt against $20.8 billion of cash and marketable securities.
    Johnson & Johnson Form 10-Q for the quarter ended 28 June 2026 - segment income, talc, net debt, repurchases and equity. — Q2 2026 · publ. 23 July 2026 · source ↗
  3. ReportedThe debt bought Intra-Cellular, funded by approximately $9.2 billion of senior notes.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: consolidated sales, volume and price, geography, the three wholesalers, rebate accruals, costs, R&D and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  4. ReportedInterest expense rose to $971 million from $755 million.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - financial statements and notes: income statement, balance sheet, cash flows, equity, segment income, acquisitions and geographic assets. — FY2025 · publ. 11 February 2026 · source ↗
  5. ReportedThe concern is the direction: 2025's net debt was higher than at the end of 2022, when J&J had just paid $17.1 billion for Abiomed and net debt was $17.4 billion.
    Johnson & Johnson Form 10-K for fiscal 2023 - the Kenvue initial public offering and exchange offer, and 2021-2022 restated to continuing operations. — FY2023 · publ. February 2024 · source ↗
  6. ReportedTotal debt was $47.9 billion at the end of 2025 against $36.6 billion a year earlier, and the company says operating cash flows, external funding and committed credit facilities will provide sufficient resources for its needs, including the remaining talc and opioid payments.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1A risk factors, Note 19 legal proceedings (talc, Innovative Health, Auris, Tracleer) and the Inflation Reduction Act. — FY2025 · publ. 11 February 2026 · source ↗
  7. ReportedTotal debt was $47.9 billion at the end of 2025 against $36.6 billion a year earlier, and the company says operating cash flows, external funding and committed credit facilities will provide sufficient resources for its needs, including the remaining talc and opioid payments.
    Johnson & Johnson Form 10-Q for the quarter ended 28 June 2026 - segment income, talc, net debt, repurchases and equity. — Q2 2026 · publ. 23 July 2026 · source ↗
  8. ReportedCash and cash equivalents were $19,709 million at the end of 2025 against $24,105 million a year earlier, and the company averaged $22.3 billion of cash and marketable securities through the year.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - financial statements and notes: income statement, balance sheet, cash flows, equity, segment income, acquisitions and geographic assets. — FY2025 · publ. 11 February 2026 · source ↗
  9. ReportedCash and cash equivalents were $19,709 million at the end of 2025 against $24,105 million a year earlier, and the company averaged $22.3 billion of cash and marketable securities through the year.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - financial statements and notes: income statement, balance sheet, cash flows, equity, segment income, acquisitions and geographic assets. — FY2025 · publ. 11 February 2026 · source ↗
Sources
Generated September 24, 2026